Financial News
Articles published by Evotec AG

From Evotec AG
Via AccessWire



Evotec and Bristol Myers Squibb Extend and Expand Strategic Partnership in Protein Degradation
May 10, 2022
From Evotec AG
Via AccessWire
Tickers
EVO





Evotec Receives € 3 m Milestone Payment for Bayer Starting Phase II Clinical Development of DNP Programme
March 21, 2022
From Evotec AG
Via AccessWire
Tickers
EVO

Evotec Presents Strategic Roadmap Towards Precision Medicine and Confirms Goals of Action Plan 2025 at Capital Markets Day
March 02, 2022
From Evotec AG
Via AccessWire
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Tickers
EVO

Evotec Expands Molecular Patient Database with Unique Nephrotic Syndrome Cohort from the University of Bristol
March 01, 2022
From Evotec AG
Via AccessWire
Tickers
EVO

Bayer Discontinues Clinical Development Candidate Eliapixant (BAY1817080), Evotec Regains the Rights to all P2X3 Assets
February 04, 2022
From Evotec AG
Via AccessWire
Tickers
EVO

Evotec Enters iPSC-based Drug Discovery Partnership with Boehringer Ingelheim in Ophthalmology
January 25, 2022
From Evotec AG
Via AccessWire
Tickers
EVO






Evotec SE Reports Results for the First Nine Months 2021 and Provides Corporate Update
November 11, 2021
From Evotec AG
Via AccessWire
Topics
Initial Public Offering

Evotec Reaches Programme Designations in Neuroscience Collaboration with Bristol Myers Squibb
November 10, 2021
From Evotec AG
Via AccessWire
Exposures
Product Safety
Tickers
EVO

Evotec SE Announces Closing of Public Offering
November 09, 2021
From Evotec AG
Via AccessWire
Tickers
EVO

Evotec SE Announces Placement of Its Public Offering of American Depositary Shares
November 03, 2021
From Evotec AG
Via AccessWire
Topics
Regulatory Compliance



Evotec Provides Preliminary Nine Month Financial Results
October 26, 2021
From Evotec AG
Via AccessWire

Evotec SE files Registration Statement for Proposed Offering of American Depositary Shares
October 11, 2021
From Evotec AG
Via AccessWire
Topics
Regulatory Compliance


Evotec Announces Bristol Myers Squibb Opt-in of EVT8683 as the First Programme from iPSC-based Neurodegeneration Collaboration
September 02, 2021
From Evotec AG
Via AccessWire
Exposures
Product Safety

Just - Evotec Biologics Opens J.POD 1 US in Redmond, Washington
August 11, 2021
From Evotec AG
Via AccessWire
Exposures
COVID-19

From Evotec AG
Via AccessWire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.